$2.21
-0.21-8.68%
At close: Jun 5, 5:00 PM EST
$2.20
-0.01-0.45%
After Hours: Jun 5, 7:39 PM EST
Adial Pharmaceuticals Inc Analyst Ratings
ADILNASDAQ
Adial Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:ADIL | Benzinga
Adial Pharmaceuticals Inc has a consensus price target of $5.17 based on the ratings of 3 analysts. The high is $8 issued by Rodman & Renshaw on November 14, 2024. The low is $1.5 issued by Maxim Group on September 30, 2025. The 3 most-recent analyst ratings were released by Maxim Group, Rodman & Renshaw, and Brookline Capital on September 30, 2025, November 14, 2024, and July 11, 2023, respectively. With an average price target of $5.17 between Maxim Group, Rodman & Renshaw, and Brookline Capital, there's an implied 134.85% upside for Adial Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Maxim Group
Rodman & Renshaw
Brookline Capital
1calculated from analyst ratings
Analyst Ratings for Adial Pharmaceuticals
Loading calendar...
FAQ
What is the target price for Adial Pharmaceuticals (ADIL) stock?
The latest price target for Adial Pharmaceuticals (NASDAQ:ADIL) was reported by Maxim Group on September 30, 2025. The analyst firm set a price target for $1.50 expecting ADIL to fall to within 12 months (a possible -31.82% downside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Adial Pharmaceuticals (ADIL)?
The latest analyst rating for Adial Pharmaceuticals (NASDAQ:ADIL) was provided by Maxim Group, and Adial Pharmaceuticals upgraded their buy rating.
When was the last upgrade for Adial Pharmaceuticals (ADIL)?
The last upgrade for Adial Pharmaceuticals Inc happened on September 30, 2025 when Maxim Group raised their price target to $1.5. Maxim Group previously had a hold for Adial Pharmaceuticals Inc.
When was the last downgrade for Adial Pharmaceuticals (ADIL)?
There is no last downgrade for Adial Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Adial Pharmaceuticals (ADIL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adial Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adial Pharmaceuticals was filed on September 30, 2025 so you should expect the next rating to be made available sometime around September 30, 2026.
Is the Analyst Rating Adial Pharmaceuticals (ADIL) correct?
While ratings are subjective and will change, the latest Adial Pharmaceuticals (ADIL) rating was a upgraded with a price target of $0.00 to $1.50. The current price Adial Pharmaceuticals (ADIL) is trading at is $2.20, which is out of the analyst’s predicted range.
